119 related articles for article (PubMed ID: 35525732)
1. Enhanced activity of AZD5582 and SM-164 in rabies virus glycoprotein-lactoferrin-liposomes to downregulate inhibitors of apoptosis proteins in glioblastoma.
Kuo YC; Lee YJ; Rajesh R
Biomater Adv; 2022 Feb; 133():112615. PubMed ID: 35525732
[TBL] [Abstract][Full Text] [Related]
2. Optimized lipopolymers with curcumin to enhance AZD5582 and GDC0152 activity and downregulate inhibitors of apoptosis proteins in glioblastoma multiforme.
Kuo YC; Yen MH; De S; Rajesh R; Tai CK
Biomater Adv; 2023 Nov; 154():213639. PubMed ID: 37793310
[TBL] [Abstract][Full Text] [Related]
3. A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer.
Moon JH; Shin JS; Hong SW; Jung SA; Hwang IY; Kim JH; Choi EK; Ha SH; Kim JS; Kim KM; Hong DW; Kim D; Kim YS; Kim JE; Kim KP; Hong YS; Choi EK; Lee JS; Hattersley M; Jin DH; Kim TW
Oncotarget; 2015 Sep; 6(29):26895-908. PubMed ID: 26314849
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous XIAP and cIAP1/2 inhibition by a dimeric SMAC mimetic AZD5582 induces apoptosis in multiple myeloma.
Kikuchi S; Sugama Y; Takada K; Kamihara Y; Wada A; Arihara Y; Nakamura H; Sato T
J Pharmacol Sci; 2024 Jan; 154(1):30-36. PubMed ID: 38081681
[TBL] [Abstract][Full Text] [Related]
5. SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP.
Lu J; Bai L; Sun H; Nikolovska-Coleska Z; McEachern D; Qiu S; Miller RS; Yi H; Shangary S; Sun Y; Meagher JL; Stuckey JA; Wang S
Cancer Res; 2008 Nov; 68(22):9384-93. PubMed ID: 19010913
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment.
Lu J; McEachern D; Sun H; Bai L; Peng Y; Qiu S; Miller R; Liao J; Yi H; Liu M; Bellail A; Hao C; Sun SY; Ting AT; Wang S
Mol Cancer Ther; 2011 May; 10(5):902-14. PubMed ID: 21372226
[TBL] [Abstract][Full Text] [Related]
7. Brain Targeted Gold Liposomes Improve RNAi Delivery for Glioblastoma.
Grafals-Ruiz N; Rios-Vicil CI; Lozada-Delgado EL; Quiñones-Díaz BI; Noriega-Rivera RA; Martínez-Zayas G; Santana-Rivera Y; Santiago-Sánchez GS; Valiyeva F; Vivas-Mejía PE
Int J Nanomedicine; 2020; 15():2809-2828. PubMed ID: 32368056
[TBL] [Abstract][Full Text] [Related]
8. Smac mimetics can provoke lytic cell death that is neither apoptotic nor necroptotic.
Miles MA; Caruso S; Baxter AA; Poon IKH; Hawkins CJ
Apoptosis; 2020 Aug; 25(7-8):500-518. PubMed ID: 32440848
[TBL] [Abstract][Full Text] [Related]
9. Neuroprotection against apoptosis of SK-N-MC cells using RMP-7- and lactoferrin-grafted liposomes carrying quercetin.
Kuo YC; Tsao CW
Int J Nanomedicine; 2017; 12():2857-2869. PubMed ID: 28435263
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel class of dimeric Smac mimetics as potent IAP antagonists resulting in a clinical candidate for the treatment of cancer (AZD5582).
Hennessy EJ; Adam A; Aquila BM; Castriotta LM; Cook D; Hattersley M; Hird AW; Huntington C; Kamhi VM; Laing NM; Li D; MacIntyre T; Omer CA; Oza V; Patterson T; Repik G; Rooney MT; Saeh JC; Sha L; Vasbinder MM; Wang H; Whitston D
J Med Chem; 2013 Dec; 56(24):9897-919. PubMed ID: 24320998
[TBL] [Abstract][Full Text] [Related]
11. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells.
Metwalli AR; Khanbolooki S; Jinesh G; Sundi D; Shah JB; Shrader M; Choi W; Lashinger LM; Chunduru S; McConkey DJ; McKinlay M; Kamat AM
Cancer Biol Ther; 2010 Nov; 10(9):885-92. PubMed ID: 20814238
[TBL] [Abstract][Full Text] [Related]
12. Potent and selective small-molecule inhibitors of cIAP1/2 proteins reveal that the binding of Smac mimetics to XIAP BIR3 is not required for their effective induction of cell death in tumor cells.
Sun H; Lu J; Liu L; Yang CY; Wang S
ACS Chem Biol; 2014 Apr; 9(4):994-1002. PubMed ID: 24521431
[TBL] [Abstract][Full Text] [Related]
13. Combined integrin α
Qi N; Zhang S; Zhou X; Duan W; Gao D; Feng J; Li A
J Nanobiotechnology; 2021 Dec; 19(1):446. PubMed ID: 34949198
[TBL] [Abstract][Full Text] [Related]
14. Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis.
Yang D; Zhao Y; Li AY; Wang S; Wang G; Sun Y
Breast Cancer Res Treat; 2012 May; 133(1):189-99. PubMed ID: 21901386
[TBL] [Abstract][Full Text] [Related]
15. AZD5582, an IAP antagonist that leads to apoptosis in head and neck squamous cell carcinoma cell lines and is eligible for combination with irradiation.
Kadletz L; Enzenhofer E; Kotowski U; Altorjai G; Heiduschka G
Acta Otolaryngol; 2017 Mar; 137(3):320-325. PubMed ID: 27739348
[TBL] [Abstract][Full Text] [Related]
16. Radiosensitization of head and neck squamous cell carcinoma by a SMAC-mimetic compound, SM-164, requires activation of caspases.
Yang J; McEachern D; Li W; Davis MA; Li H; Morgan MA; Bai L; Sebolt JT; Sun H; Lawrence TS; Wang S; Sun Y
Mol Cancer Ther; 2011 Apr; 10(4):658-69. PubMed ID: 21282353
[TBL] [Abstract][Full Text] [Related]
17. Smac mimetic SM-164 potentiates APO2L/TRAIL- and doxorubicin-mediated anticancer activity in human hepatocellular carcinoma cells.
Zhang S; Li G; Zhao Y; Liu G; Wang Y; Ma X; Li D; Wu Y; Lu J
PLoS One; 2012; 7(12):e51461. PubMed ID: 23240027
[TBL] [Abstract][Full Text] [Related]
18. Facile synthesis of lactoferrin conjugated ultra small large pore silica nanoparticles for the treatment of glioblastoma.
Janjua TI; Ahmed-Cox A; Meka AK; Mansfeld FM; Forgham H; Ignacio RMC; Cao Y; McCarroll JA; Mazzieri R; Kavallaris M; Popat A
Nanoscale; 2021 Oct; 13(40):16909-16922. PubMed ID: 34533167
[TBL] [Abstract][Full Text] [Related]
19. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
[TBL] [Abstract][Full Text] [Related]
20. Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model.
Lakkadwala S; Singh J
Colloids Surf B Biointerfaces; 2019 Jan; 173():27-35. PubMed ID: 30261346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
